{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-308144","form_type":"8-K","ticker":"KMTS","cik":"0001877184","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","filed_at":"2025-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.947382+00:00","generated_at":"2026-05-16T14:55:09.691562+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kestra Medical closes $148.4M public offering of 6.9M shares at $23.00","bullets":["Offered 6,900,000 common shares at $23.00 per share, including full exercise of underwriters' over-allotment option of 900,000 shares.","Net proceeds of approximately $148.4 million after underwriting discounts and estimated offering expenses.","Proceeds to support sales/marketing, commercialization, R&D, clinical studies, and working capital.","Underwriters included BofA Securities, Piper Sandler, J.P. Morgan, and Goldman Sachs; offering closed December 4, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-308144","json":"https://secwatch.observer/filing/0001193125-25-308144.json","markdown":"https://secwatch.observer/filing/0001193125-25-308144.md","text":"https://secwatch.observer/filing/0001193125-25-308144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1877184/000119312525308144/0001193125-25-308144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1877184/000119312525308144/d92377d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:55:09.691562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf88cb5d7dc0cff6dc8f4b9ba3370e272990bce6","claim":"KESTRA MEDICAL TECHNOLOGIES, LTD. entered into Underwriting Agreement with BofA Securities, Inc., Piper Sandler & Co., J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein valued at approximately $148.4 million (effective 2025-12-02).","evidence_excerpt":"On December 2, 2025, Kestra Medical Technologies, Ltd., a Bermuda exempted company (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc., Piper Sandler & Co., J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), related to an underwritten public offering (the “ Offering ”) of 6,900,000 common shares, par value $1.00 per share (the “ Common Shares ”), at a purchase price per share of $23.00 (the “ Offering Price ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1877184/000119312525308144/0001193125-25-308144-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"BofA Securities, Inc., Piper Sandler & Co., J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein"},{"label":"Value","value":"approximately $148.4 million"},{"label":"Effective","value":"2025-12-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}